Retatrutide and Bodybuilding: Body Composition Data

The Short Answer

Retatrutide has drawn a lot of interest in bodybuilding and fitness circles. The reasons are its triple receptor profile (GIP/GLP-1/glucagon), the largest mean weight reductions reported in any late-stage obesity trial, and the possible metabolic edge from glucagon receptor agonism. Phase 2 DXA body composition data, published by Coskun and colleagues in The Lancet Diabetes & Endocrinology (2025), give the most detailed look at how retatrutide affects fat mass, lean mass and where fat is lost.

The data show large fat loss, with lean mass holding up about as well as with other incretin-based obesity drugs. But retatrutide is an investigational drug. It is not approved, not available in clinical-grade form, and comes with significant adverse events, including a dysesthesia signal that affected up to 20.9% of participants at the highest dose.

What follows is the clinical evidence. We do not endorse off-label use of any investigational compound.

Why Bodybuilders Are Interested

Bodybuilders’ interest in retatrutide comes down to a few drug properties that set it apart from other incretin-based therapies:

1. Triple receptor agonism. Retatrutide activates GIP, GLP-1 and glucagon receptors. The glucagon component is unique among obesity drugs in clinical development and could, in theory, boost thermogenesis and fat burning.
2. Record weight loss. TRIUMPH-4 showed -28.7% mean body weight loss at 12 mg over 68 weeks, the largest reduction in any Phase 3 obesity trial. For bodybuilders chasing aggressive fat loss in a cut, an effect this size gets attention.
3. Glucagon-driven thermogenesis. In animal models, glucagon receptor activation raises resting energy expenditure and promotes brown fat thermogenesis. That has led to speculation that retatrutide might burn fat better than GLP-1-only or GIP/GLP-1 dual agonists.
4. Visceral fat. Glucagon receptor activity is thought to act on liver and abdominal fat, which appeals to physique athletes who want visible abs.

These features have made retatrutide a hot topic on bodybuilding forums, YouTube channels and in fitness media. The clinical data, though, are more mixed than the hype suggests.

Body Composition Data: Coskun 2025 (Lancet D&E)

The most useful dataset on retatrutide and body composition comes from a DXA substudy within the Phase 2 trial, published by Coskun and colleagues in The Lancet Diabetes & Endocrinology in 2025.

Study Parameters

• Enrolled: 189 participants in the DXA substudy
• Completed DXA scans at 36 weeks: 103 participants
• Completion rate: about 55%, a significant limitation when reading the results
• Population: This substudy was done in people with type 2 diabetes, not the general obesity population. Body composition responses may differ between the two.
• Duration: 36 weeks (shorter than the 48-week Phase 2 primary endpoint and the 68-week Phase 3 duration)
• Doses evaluated: 0.5 mg, 4 mg, 8 mg and 12 mg (Phase 2 doses; the Phase 3 program uses 9 mg and 12 mg with an updated escalation protocol including a 6 mg step)

Fat Mass Reduction

The apparent plateau, or slight drop, in fat mass reduction from 8 mg to 12 mg should be read with care, given the small numbers at each dose and the 45% dropout rate in the DXA substudy.

Fat-to-Lean Mass Loss Ratio

The authors concluded that the share of lean mass lost, relative to total weight lost, was similar to other obesity treatments. We have not given an exact fat-to-lean ratio for each dose because we could not confirm one against the paper; figures quoted online differ.

For bodybuilders, this ratio is a key number. Total weight loss tells you less than what that weight was made of. A drug that gives 30% weight loss but strips 50% lean mass is a very different thing from one that spares muscle.

How Does Retatrutide Compare?

No direct head-to-head comparisons have been done, though, and differences in study populations, durations and measurement methods make cross-trial comparisons imprecise.

Absolute Lean Mass Loss

A ratio should not hide the absolute numbers. Participants on the higher doses lost lean mass as well as fat. Because total weight loss on retatrutide is large, even a typical share of lean mass adds up to several kilograms of lean tissue.

For bodybuilders who have spent years building muscle, that is a real concern. No one has studied whether resistance training and high protein intake can limit this loss in people taking retatrutide.

Android (Visceral) Fat Reduction

The substudy also measured android fat, the visceral and subcutaneous fat around the abdomen. We have not listed a figure because we could not confirm it against the published paper.

Losing visceral fat matters for both metabolic health and appearance. Android fat sits over the abdominal muscles, so reducing it directly sharpens visible definition there.

The Glucagon Receptor Question

The glucagon receptor component is what most sets retatrutide apart from semaglutide and tirzepatide when it comes to body composition. Glucagon receptor activation has several effects relevant to fat loss:

Animal Data

• Higher resting energy expenditure (REE): Glucagon stimulates heat production in the liver and raises metabolic rate in rodents
• Brown adipose tissue activation: Glucagon drives brown fat thermogenesis, turning stored energy into heat instead of storing it
• More fat burning: Glucagon shifts the body toward burning fatty acids for fuel
• Hepatic lipid mobilization: Glucagon promotes the release of stored triglycerides from the liver

Human Relevance: Uncertain

How much glucagon receptor agonism matters for body composition in humans is still unclear:

• Humans have far less brown adipose tissue than rodents, and how much it adds to total energy expenditure is debated
• Phase 2 indirect calorimetry data for retatrutide have not been published
• Human studies have not separated the rise in resting energy expenditure due to the glucagon component from that due to the GLP-1 and GIP components
• The liver fat reduction seen with retatrutide (82% at 12 mg in Phase 2a) may reflect glucagon-driven fat release from the liver, but that does not mean more subcutaneous fat is lost

Bodybuilders’ enthusiasm about glucagon-driven thermogenesis rests mostly on animal data and theory. Whether it gives humans a real fat-loss advantage beyond what GLP-1 agonism alone provides is unproven.

Clinical Trial Context: What Participants Actually Did

The Phase 2 trial that produced the body composition data included basic lifestyle measures:

• Caloric deficit: 500 kcal/day below estimated maintenance
• Physical activity: 150 minutes per week of moderate-intensity exercise

By bodybuilding standards, these are modest. Participants were adults with obesity (mean BMI ~37), not trained athletes. No resistance training program was set, and protein intake was not standardized beyond general dietary advice.

This context matters. The body composition results reflect retatrutide in a sedentary-to-moderately-active obese population eating a standard deficit diet. Results in resistance-trained people eating high-protein diets and doing structured hypertrophy or strength training could be quite different, but no one has studied that group.

Protein and Training Recommendations from the Literature

There are no retatrutide-specific guidelines for body composition, but the wider obesity drug literature and exercise science suggest the following:

Protein Intake

• 1.2-2.0 g/kg/day of protein is recommended during caloric restriction to limit lean mass loss
• The upper end of this range (1.6-2.0 g/kg/day) may matter most during aggressive weight loss, which retatrutide certainly produces
• GLP-1 agonists cut appetite sharply, which can make high protein intake hard to reach, so you need to put protein first when planning meals
• Spreading protein across 3-4 meals with 30-40g each may further support muscle protein synthesis

Resistance Training

• 2-5 sessions per week of resistance training is the most effective way to preserve lean mass during caloric restriction
• Keep applying progressive overload even while losing weight
• Prioritize compound movements that work large muscle groups
• You may need to manage training volume carefully because of the GI side effects common with GLP-1 agonists (nausea, vomiting, diarrhea), and adjust when you train relative to meals and injections

What Has Not Been Studied

No clinical trial has tested retatrutide together with:

• Structured resistance training programs
• High-protein diets (>1.5 g/kg/day)
• Other body composition strategies common in bodybuilding
• Anabolic androgenic steroids or other performance-enhancing compounds

Without these data, any claims about retatrutide in a trained, protein-optimized population are extrapolation, not evidence.

Critical Warnings

Retatrutide Is Not Approved

As of October 31, 2026, retatrutide has no FDA approval, no EMA approval and no marketing authorization anywhere in the world. No pharmaceutical-grade product is available to buy. Anything sold online as “retatrutide” is not made under GMP conditions and has no quality verification for identity, purity, potency or sterility.

Gray Market Peptide Risks

Products sold as retatrutide by research peptide vendors carry built-in risks:

• Unknown identity and purity: Independent testing of gray-market peptides has repeatedly found gaps between label claims and actual content
• No sterility assurance: Injectable products need validated sterility processes that unregulated vendors cannot guarantee
• No dose accuracy: Without validated potency testing, the real amount of peptide per vial is unknown, so accurate dosing is impossible
• No batch traceability: Quality problems cannot be tracked or recalled

Dysesthesia Is Not a Minor Side Effect

The dysesthesia signal seen in TRIUMPH-4 deserves special emphasis for bodybuilders, a group that sometimes downplays side effects:

• 20.9% incidence at 12 mg (vs. 0.7% placebo)
• 8.8% incidence at 9 mg
• Described as tingling, numbness or burning, mostly in the hands and feet
• The mechanism is not fully understood
• If you rely on neuromuscular control and body awareness during heavy lifting, disturbed sensory nerves are not a trivial matter

Discontinuation Rates

• 18.2% of participants at 12 mg stopped treatment because of adverse events in TRIUMPH-4
• That was in a medically supervised group with structured dose escalation; rates could be higher with unsupervised self-dosing

No Data on Compound Interactions

Many bodybuilders use several drugs at once. There are zero data on interactions between retatrutide and:

• Anabolic androgenic steroids (testosterone, nandrolone, trenbolone, etc.)
• Selective androgen receptor modulators (SARMs)
• Growth hormone or growth hormone secretagogues
• Insulin or insulin sensitizers
• Thyroid hormones (T3, T4)
• Stimulants or thermogenics (clenbuterol, ephedrine, caffeine)
• Diuretics

Combining an investigational triple receptor agonist with other compounds, with no interaction data at all, is a risk no one has measured.

Frequently Asked Questions

Is retatrutide better than semaglutide for cutting?

Retatrutide gives more total weight loss than semaglutide (28.7% vs. ~15% at Phase 3 doses). The authors of retatrutide’s Phase 2 DXA substudy described its share of lean mass loss as similar to other obesity treatments (semaglutide showed about 35-40% lean loss in the STEP-1 trial; Wilding et al., NEJM 2021). But these comparisons span different trials with different populations and durations. No head-to-head study has compared the two for body composition, and neither has been studied in resistance-trained people.

Does retatrutide preserve muscle better than other GLP-1 drugs?

In the Phase 2 DXA substudy, the authors described the share of weight lost as lean mass as similar to other obesity treatments; no head-to-head comparison exists. Lean mass still fell at the higher doses over 36 weeks. No one has studied whether resistance training and high protein intake can improve this ratio in people taking retatrutide.

Does the glucagon component give retatrutide an edge for fat loss?

In theory, glucagon receptor activation raises resting energy expenditure and increases fat burning. In animal models these effects are well documented. In humans, how much they matter clinically is unclear. No published data separate the glucagon component’s share of retatrutide’s fat loss from that of the GLP-1 and GIP components.

Does retatrutide have any role during weight gain or muscle-building phases?

There is no clinical reason to use a potent appetite suppressant and weight loss drug during a calorie surplus meant for building muscle. Retatrutide sharply reduces appetite and food intake, which runs directly against the calorie needs of a bulking phase. Its GI side effects (nausea in 43.2%, vomiting in 20.9% at 12 mg) would also make it hard to eat the amount of food needed to gain lean mass. There are no clinical data on retatrutide during intentional weight gain.

What dose would bodybuilders use?

This question assumes access to a pharmaceutical-grade product, which does not exist outside clinical trials. The Phase 3 dose escalation protocol is 2 mg → 4 mg → 6 mg → 9 mg → 12 mg with 4-week intervals between steps. The Phase 2 body composition data were collected at doses up to 12 mg. No one has studied the best dose for body composition (as opposed to total weight loss).

Is it safe to combine retatrutide with anabolic steroids?

There are zero data on this combination. No clinical trial has studied retatrutide in people using anabolic androgenic steroids or any other performance-enhancing drugs. The metabolic, liver, cardiovascular and neurological effects of combining a triple receptor agonist with anabolic compounds are completely unknown. The risk is unknown too.

Summary

Retatrutide’s Phase 2 DXA data show large fat loss (up to 26.1% fat mass reduction at 36 weeks), with a share of lean mass loss the authors judged similar to other obesity treatments. The glucagon receptor component could in theory help with thermogenesis and fat burning, but whether those effects matter in humans is unproven. Absolute lean mass loss is still a concern, and there are no data on retatrutide in resistance-trained, protein-optimized people. Retatrutide is investigational, not approved and not available in clinical-grade form. The dysesthesia signal (20.9% at 12 mg) and high GI adverse event rates are real safety concerns that should not be played down. There are no data on interactions with anabolic steroids or other compounds common in bodybuilding.